Effect of Dietary Cocoa Tea (<i>Camellia ptilophylla</i>) Supplementation on High-Fat Diet-Induced Obesity, Hepatic Steatosis, and Hyperlipidemia in Mice

Yang, Xiao Rong; Wat, Elaine; Wang, Yan Ping; Ko, Chun Hay; Koon, Chi Man; Siu, Wing Sum; Gao, Si; Cheung, David Wing Shing; Lau, Clara Bik San; Ye, Chuang Xing; Leung, Ping Chung

doi:https://doi.org/10.1155/2013/783860

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Materials and Methods Results Discussion References Copyright Related Articles

Special Issue

Natural Products for the Treatment of Obesity, Metabolic Syndrome, and Type 2 Diabetes

View this Special Issue

Research Article | Open Access

Volume 2013 | Article ID 783860 | https://doi.org/10.1155/2013/783860

Effect of Dietary Cocoa Tea (Camellia ptilophylla) Supplementation on High-Fat Diet-Induced Obesity, Hepatic Steatosis, and Hyperlipidemia in Mice

Xiao Rong Yang,^1,2Elaine Wat ,^3,4Yan Ping Wang,^3,4Chun Hay Ko,^3,4,5Chi Man Koon,^3,4Wing Sum Siu,^3,4Si Gao,^3,4David Wing Shing Cheung,^3,4Clara Bik San Lau,^3,4,5Chuang Xing Ye,²and Ping Chung Leung^3,4,5

Academic Editor: Ravirajsinh Jadeja

Received15 Mar 2013

Revised13 Jun 2013

Accepted18 Jun 2013

Published09 Jul 2013

Abstract

Recent studies suggested that green tea has the potential to protect against diet-induced obesity. The presence of caffeine within green tea has caused limitations. Cocoa tea (Camellia ptilophylla) is a naturally decaffeinated tea plant. To determine whether cocoa tea supplementation results in an improvement in high-fat diet-induced obesity, hyperlipidemia and hepatic steatosis, and whether such effects would be comparable to those of green tea extract, we studied six groups of C57BL/6 mice that were fed with (1) normal chow (N); (2) high-fat diet (21% butterfat + 0.15% cholesterol, wt/wt) (HF); (3) a high-fat diet supplemented with 2% green tea extract (HFLG); (4) a high-fat diet supplemented with 4% green tea extract (HFHG); (5) a high-fat diet supplemented with 2% cocoa tea extract (HFLC); and (6) a high-fat diet supplemented with 4% cocoa tea extract (HFHC). From the results, 2% and 4% dietary cocoa tea supplementation caused a dose-dependent decrease in (a) body weight, (b) fat pad mass, (c) liver weight, (d) total liver lipid, (e) liver triglyceride and cholesterol, and (f) plasma lipids (triglyceride and cholesterol). These data indicate that dietary cocoa tea, being naturally decaffeinated, has a beneficial effect on high-fat diet-induced obesity, hepatomegaly, hepatic steatosis, and elevated plasma lipid levels in mice, which are comparable to green tea. The present findings have provided the proof of concept that dietary cocoa tea might be of therapeutic value and could therefore provide a safer and cost effective option for patients with diet-induced metabolic syndrome.

1. Introduction

Metabolic syndrome refers to the clusters of risk factors that would lead to increased episodes of cardiovascular disease (CVD). These risk factors include age, family history of CVD, gender, obesity, insulin resistance, nonalcoholic fatty liver (NAFLD), dyslipidemia, hypertension, and type 2 diabetes [1, 2]. According to the American Association of Clinical Endocrinologists and the International Diabetes Federation (IDF), metabolic syndrome can be defined as a complex of symptoms with central obesity (with waist circumference of >102 cm in men or >88 cm in women), plus two or more of the following factors: elevated serum levels of triglycerides, hyperglycemia, elevated blood pressure, and reduced serum levels of high-density lipoprotein- (HDL-) associated cholesterol [3].

Because of the current epidemic of over-nutrition and sedentary lifestyle worldwide, metabolic syndrome is becoming more common, particularly in developed countries. According to the report from the National Cholesterol Education Program (NCEP), the prevalence of metabolic syndrome is high, with a rate of 35.1% for middle-aged men and 32.6% for middle-aged women in the United States [3, 4]. However, since the pathogenesis of metabolic syndrome has multiple metabolic origins, pharmacological approaches often consist of separate drugs which target at individual risk factors: lipid-lowering drugs, antihypertensive agents, hypoglycemic drugs, antiplatelet drugs, and weight-loss agents [5, 6]. These drugs nonetheless pose various side effects risks. Functional foods or nutraceuticals which have potentially important antiobesity properties have thus attracted great attention.

Tea (Camellia sinensis) is one of the most consumed beverages in the world, second only to water [7, 8]. Depending on the fermentation process, tea can be classified into three main types: the “nonfermented” green tea, the “semifermented” oolong tea, and the “fully fermented” black/red tea [9]. Due to the differences in processing, the chemical compositions of tea also differ, leading to the differences in the biological properties of different types of tea extracts [8]. Whereas the fully fermented black tea contains theaflavins and thearubigins as products from catechins oxidation, green tea has only undergone minimal fermentation and therefore contains predominately catechins [10]. It is estimated that a typical brewed green tea beverage (2.5 g green tea in 250 mL hot water) usually contains approximately 240–320 mg catechins including (−)-epicatechin (EC), (−)-epigallocatechin (EGC), (−)-epicatechin-3-gallate (ECG), epigallocatechin-3-gallate (EGCG), (+)-catechin (C), and (+)-gallocatechin (GC) [10–12]. EGCG is the most abundant catechin present in green tea comprising approximately 30–50% of the total catechins content [13]. In addition to the catechin constituents, green tea also contains considerably high amounts of caffeine (3–6%) [11, 12, 14]. Although it has been well documented that green tea consumption could exhibit antiobesity, hypolipidemic, and hypoglycaemic properties and thereby improving CVD health, effects of caffeine contents within green tea on CVD have been contradictive [15, 16]. The various negative effects that caffeine poses on human behaviours [17] and sleep deprivation [18] have also caused great dilemma to obese or diabetic individuals. There is thus an urge for the market to search for decaffeinated green tea which could pose similar health benefits [19].

Cocoa tea (Camellia ptilophylla), which belongs to the genus Camellia, is a naturally decaffeinated tea plant. For many years, it has been widely consumed by local inhabitants in the Longmen area of Guangdong Province of China but has only started attracting scientific interest since 1988 [20, 21]. Early work suggested that cocoa tea exhibits profound cytotoxic effect on various cancer cell lines including HeLa, CNE2, and MGC-803 [22]. Peng et al. also demonstrated the potential of cocoa tea extract to inhibit prostate cancer cell proliferation and tumour growth in vivo and in vitro [23]. More recently, our laboratory showed that administration of cocoa tea to HepG2 xenograft nude mice resulted in dose-dependent reduction in tumour growth via caspase-3-regulated pathway [24]. Despite having high catechins content, the beneficial effects of cocoa tea on cardiovascular health have not been studied in details. Kurihara et al. demonstrated that a single oral administration of 500 mg/kg of cocoa tea extract significantly suppressed plasma triglyceride (TG) induction in mice given 5 mL/kg of lard oil [25]. Although this experiment suggested the potential of cocoa tea extract to reduce plasma TG, this effect is acute and the chronic effect of cocoa tea remains to be determined. Furthermore, there exists no experimental data on the effects of cocoa tea on diet-induced obesity and NAFLD. In order to determine whether cocoa tea supplementation to a high-fat diet results in an improvement in obesity and plasma and liver lipid levels, we carried out the present study in C57BL/6 mice to compare the effects of different doses of cocoa tea and green tea supplementations on high-fat diet-induced metabolic syndrome.

2. Materials and Methods

2.1. Herbal Materials Preparation

Green tea leaves were purchased from renowned supplier in China. Cocoa tea leaves were obtained from the Tea Research Institute, Guangdong Academy of Agricultural Sciences, China. Herbarium voucher specimens of the green tea and cocoa tea were deposited at the museum of the Institute of Chinese Medicine, the Chinese University of Hong Kong, with voucher specimen numbers 3336 and 3401, respectively. For the extracts preparation, green tea or cocoa tea leaves (100 g) were brewed 3 times, each with 1 L of hot distilled water (80°C) for 15 min. The infusion was then cooled to room temperature and filtered with cellulose filter paper (0.45 μm, Millipore, Billerica, MA, USA). The filtrate was then concentrated using a vacuum rotary evaporator. The resulting extracts were freeze-dried overnight to produce tea powder.

2.2. HPLC Analysis of Tea Aqueous Extract

High-performance liquid chromatography (HPLC) analysis was performed using Hewlett Packard Agilent 1100 series HPLC System, equipped with G1329A ALS Autosampler and G1315A Diode Array Detector (Agilent Technologies, USA). Sample solution was injected onto a Supelco Discovery RP Amide C16 guard column (15 cm × 4.6 mm, 5 μm) (Sigma-Aldrich, Inc., USA). All solvents were prefiltered with 0.45 μm Millipore filter disk (Millipore, MA, USA) and degassed. A gradient elution was carried out using the following solvent systems: mobile phase A: double distilled water/phosphoric acid (99.95/0.05; v/v); mobile phase B: acetonitrile. The elution was performed with a gradient procedure as follows: 0-1 min, 2% B; 2–60 min, from 2% B to 98% B. The column heater was kept at 35°C. The flow rate used was 0.8 mL/min, and detection was performed at 210 nm. Each sample (10 μL) was injected into the column after filtration through a 0.45 μm filter disk. Identification of the tea polyphenols was carried out by comparing the retention times and the UV absorbance of the unknown peaks to those of the standards. A standard mixture containing theanine (Thea), theobromine (TB), caffeine (CAF), epigallocatechin (EGC), catechin (C), epicatechin (EC), epigallocatechin gallate (EGCG), gallocatechin (GC), gallocatechin gallate (GCG), and epicatechin gallate (ECG) in methanol was prepared and analyzed. Calibration curves for standard mixture was carried out using standard solutions injecting with volumes: 5, 10, and 20 μL. The system was monitored by a computer equipped with the 32 Karat Software (Beckman Instrument Inc., Fullerton, CA, USA) for data collection, integration, and analysis.

2.3. Animals and Diets

Eight-week-old male C57BL/6 mice were obtained from the Laboratory Animal Services Centre (LASEC) of the Chinese University of Hong Kong. The care and use of the animals were in compliance with the institutional guidelines, and the experimental procedures were approved by the Animal Experimentation Ethics Committee of the CUHK. Animals were housed in standard cages (5 animals per cage) at a constant temperature of 20°C with a 12 h light/dark cycle. They were allowed ad libitum access to normal-chow diet and water. After 1 week of acclimatization, they were divided into six groups ( mice per group): (1) normal chow-fed group (N) that received normal chow diet containing 6% by weight of fat (SF04-057, Specialty Feeds, Glen Forest, Western Australia); (2) high-fat fed group (HF) that received a high-fat semipurified diet containing 21% wt/wt butterfat and 0.15% cholesterol (SF00-219, Specialty Feeds, Glen Forest, Western Australia); (3) high-fat fed group supplemented with 2% wt/wt green tea aqueous extract (HFLG); (4) high-fat fed group supplemented with 4% wt/wt green tea aqueous extract (HFHG); (5) high-fat fed group supplemented with 2% wt/wt cocoa tea aqueous extract (HFLC); and (6) high-fat fed group supplemented with 4% wt/wt cocoa tea aqueous extract (HFHC). The high-fat semipurified diet SF00-219 was formulated to be equivalent to western type diet Harlan Teklad TD88137. The normal chow diet SF04-057 was designed to be the control diet for the high-fat semipurified diet SF00-219. A detailed composition of SF00-219 and SF04-057 are summarised in Table 1. Food intake was recorded twice weekly, and body weights were measured twice a week.

2.4. Tissue Processing

Mice were fed diets for 8 weeks. At the end of the study, all mice were sacrificed after a 16-hour overnight fast. Animals were anaesthetised using a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg) i.p., and whole blood was withdrawn by cardiac puncture. Blood was collected using heparin containing tubes, and plasma was separated by centrifugation (3,000 rpm, 10 min). Plasma were used immediately for plasma lipid measurement or frozen (−80°C) for future use. Livers were immediately excised, weighed, and divided into smaller pieces for storage at −80°C (for lipid analysis) or in 4% paraformaldehyde for histological analysis. Epididymal, inguinal, and perirenal fat pads were excised and weighed.

2.5. Biochemical Analyses

Plasma triglyceride (TG) and cholesterol (Chol) concentrations were measured by enzymatic methods, using GPO-PAP and CHOD-PAP kits (Roche Diagnostics, Switzerland), respectively. Total liver lipids were determined gravimetrically after extraction by the method of Bligh and Dyer [26]. Individual hepatic lipids were quantitated enzymatically (as described above) after solubilization in isopropanol.

2.6. Histology

5 μm thick sections of paraffin embedded tissue were cut with a microtome and placed on SuperFrost Plus microscope slides (Thermo Scientific, USA). Sections were dried at 37°C overnight and dewaxed by immersion with two exchanges in histolene (2 min) followed by rehydration to water through a series of graded ethanol washes comprising two washes in absolute ethanol, two washes in 95% ethanol, and two final washes in 75% ethanol. Sections were subjected to haematoxylin and eosin (H&E) staining, according to the method of Harris [27]. They were then dehydrated using graded ethanols comprising two washes in 75% ethanol, two washes in 95% ethanol, and two washes in absolute ethanol, after which they were subjected to two changes of xylene, and mounted with dibutyl phthalate in histolene (DPX) (Sigma-Aldrich, Inc., USA). Liver samples were examined histologically after embedding in paraffin, sectioning, and staining with H&E.

2.7. Gene Expression Analysis

Hepatic mRNA levels were measured by real-time PCR. Total RNA was isolated by selective binding to a silica gel-based membrane following the lysis and homogenisation of liver samples in a denaturing guanidine thiocyanate buffer (RNeasy kit, Qiagen, USA). RNA (100 ng) was reversely transcribed into cDNA using random primers provided with the iScript cDNA Synthesis kit (Bio-Rad, USA). Selected genes were amplified using iQ SYBR Green Supermix (Bio-Rad, USA) in an iCycler system (Bio-Rad, USA) with 12 pmol of both forward and reverse primers. PCR conditions were as follows: 1 cycle of 95°C for 3 min, 50 cycles of 95°C for 30 s, 55–60°C for 30 s and 72°C for 30 s, followed by 1 cycle of 95°C for 1 min. Purity of PCR products was assessed by melt curve analysis. Relative gene expression was calculated by normalizing cycle threshold (Ct) values for genes of interest with Ct values for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or cyclophilin using the delta-delta Ct method. Primer sequences were as follows: CYCLOPHILIN (forward: 5′-CAAATGCTGGACCAAACACAA-3′; reverse: 5′-CCATCCAGCCATTCAGTCTTG-3′); GAPDH (forward: 5′-GGCATCACTGCAACTCAGAA-3′; reverse: 5′-TTCAGCTCTGGGATGACCTT-3′); HMGCR (forward: 5′-CTTGTGGAATGCCTTGTGATTG-3′; reverse: 5′-AGCCGAAGCAGCACATGAT-3′); LDL-R (forward: 5′-CTGTGGGCTCCATAGGCTATCT-3′; reverse: 5′-GCGGTCCAGGGTCATCTTC-3′); PPAR-γ (forward: 5′-CCAGAGTCTGCTGATCTGCG-3′; reverse: 5′-GCCACCTCTTTGCTCTGCTC-3′); CD36 (forward: 5′-GAACCTATTGAAGGCTTACATCC-3′; reverse: 5′-CCCAGTCACTTGTGTTTTGAAC-3′).

2.8. Statistical Analysis

Values given in the text are means ± SEM, and Prism 5 for Window (version 5.0c, GraphPad Software, Inc., USA) was used for statistical analysis. Significant differences among all groups were assessed by one-way ANOVA, followed by Bonferroni’s multiple comparison test. A probability of was considered to be statistically significant.

3. Results

3.1. Chemical Profiles of Green Tea and Cocoa Tea Extracts

Figure 1 shows the HPLC profiles of (a) green tea and (b) cocoa tea aqueous extracts, respectively. The retention time point of the standards were compared to the HPLC profiles of both tea extracts, with the quantities for each of the chemical markers within the tea extracts calculated and summarized in Table 2. Cocoa tea possessed a chemical profile different from green tea, with a relative concentration of the six major tea catechins ranked GCG > C > EGCG > EGC > ECG > EC, whereas green tea extract had a relatively higher concentration of EGCG, followed by EGC, ECG, EC, C, and GCG. Cocoa tea extract also contained theanine and theobromine, with the content of and %, respectively. Green tea extract contained a theanine composition of % and a much lower contents of theobromine (%) compared to that of cocoa tea. The caffeine contents of green tea and cocoa tea extracts were % and 0%, respectively.

(a)

(b)

3.2. Effect of Green Tea and Cocoa Tea Supplementations on Daily Food Intake, Body Weight Gain, and Final Body Weight in Mice Given High-Fat Diet

Among all the high-fat-fed animals, addition of green tea or cocoa tea extract at 2% did not affect the daily food consumption of the animals. However, 4% green tea supplementation significantly reduced daily food consumption of C57BL/6 mice ( versus g, ), whereby there was no significant difference on food intake for 4% cocoa tea supplemented group compared to HF group (Table 3). HF-fed animals gained significantly more weight than chow-fed animals ( versus g, ). Both green tea and cocoa tea supplementation significantly reduced the final body weight and total body weight gain compared to mice given high-fat diet alone in a dose-dependent manner, as shown in Table 3. There was however no significant difference on final body weight or total weight gain between 2% green tea and cocoa tea supplemented groups or between 4% green tea and cocoa tea supplemented groups.

3.3. Effect of Green Tea and Cocoa Tea Supplementations on Liver Weight and Liver to Body Weight Ratio in Mice Given High-Fat Diet

High-fat diet alone significantly increased liver weights of mice compared to mice given normal-chow diet. Mean liver weight was % higher in the HF compared to the N group (). Both 2% and 4% green tea and cocoa tea supplementations had significant effect on liver weight in HF-fed mice (Table 4). When liver weights were expressed as a ratio relative to body wt, HF had a mean of g/100 g body wt, compared to the g/100 g for normal-chow-fed mice, which did not reach statistical significance. Both green tea and cocoa tea supplemented groups significantly reduced the liver to body weight ratio dose dependently compared to HF group. The % of reduction in liver/body weight ratio were % and % for 2% and 4% green tea supplementation and % and % for 2% and 4% cocoa tea supplementation, respectively. No significant difference was observed among all tea supplemented groups.

3.4. Effect of Green Tea and Cocoa Tea Supplementations on Epididymal, Perirenal, and Inguinal Fat Pad Weight in Mice Given High-Fat Diet

High-fat diet induced obesity in C57BL/6 male mice compared to normal-chow-fed mice after 8 weeks of diet, as evidenced by the significant increase in all three types of fat pad mass: epididymal fat mass ( versus mg, ), perirenal fat mass ( versus mg, ), and inguinal fat mass ( versus mg, ) (Table 5). Both green tea and cocoa tea supplementations significantly reduced all fat pad mass in a dose-dependent manner. There was no significant difference on epididymal fat mass or epididymal fat/body wt ratio and inguinal fat mass or inguinal fat/body weight ratio between 2% green tea and cocoa tea supplemented groups and likewise between 4% green tea and cocoa tea supplemented groups. However, perirenal fat mass tended to be lower for 2% green tea supplemented group compared to 2% cocoa tea supplemented group and was significantly lower when expressed as perirenal fat wt/body wt ratio. There was however no significant difference on perirenal fat mass and perirenal fat wt/body wt ratio between 4% green tea and cocoa tea supplemented groups (Table 5).

3.5. Effect of Green Tea and Cocoa Tea Supplementations on Liver Histology and Liver Lipid Contents in Mice Given High-Fat Diet

Livers from mice given different diets were analyzed histologically, and representative stained sections are shown in Figure 2. N group animals demonstrated the histological sections of normal livers. In contrast, H&E sections from HF animals revealed the presence of a large number of circular lipid droplets in between hepatocytes. These lipid inclusions were clearly reduced in both size and number in livers of both doses of green tea- and cocoa tea-treated animals.

(a)

(b)

(c)

(d)

(e)

(f)

Figure 2

Histological appearance of liver sections of (a) a normal chow-fed mice; (b) a high-fat fed mice; (c) a high-fat fed mice supplemented with 2% green tea extract; (d) a high-fat fed mice supplemented with 4% green tea extract; (e) a high-fat fed mice supplemented with 2% cocoa tea extract; and (f) a high-fat fed mice supplemented with 4% cocoa tea extract. Sections were stained with haematoxylin and eosin. Lipid accumulation in the liver of HF-fed mice was very evident due to the presence of circular lipid droplets. Circular lipid droplets were significantly reduced in sections from both green tea and cocoa tea supplemented animals.

The beneficial effect of both tea supplementations on HF-induced hepatomegaly was associated with a significant reduction in total hepatic lipid content, expressed as mg of lipid per grams of liver (Figure 3(a)) or expressed as mg of lipid per whole liver (Figure 3(b)). Total liver lipid content (in mg/g tissue) was significantly higher in HF mice compared to N mice (% higher, ). HFLG-, HFHG-, HFLC-, and HFHC-fed mice had liver lipid levels that were significantly lower than HF-fed mice (i.e., %, %, %, and %, resp., for mg/g tissue). No significant difference was observed among green tea and cocoa tea supplemented groups at either dose. As shown in Figure 4, measurement of liver TG (a) and Chol (b) revealed that HF mice had elevated levels of both lipids compared to N mice (i.e., 1.2-fold (±0.1) increase in TG and 1.9-fold (±0.1) increase in Chol), of which only the latter had reached statistical significance. 2% and 4% green tea supplementation significantly reduced liver TG and Chol levels in HF-fed mice. Cocoa tea supplementation, on the other hand significantly reduced liver Chol at both 2% and 4% (%, , and %, ). Although both 2% and 4% cocoa tea additions resulted in reduced levels of liver TG (% and %, ), only 4% supplementation reached statistical significance.

(a)

(b)

Figure 3

Total lipid in the liver of mice fed a normal chow or high-fat diet, with or without the addition of green tea or cocoa tea supplementation at different concentrations. (a) shows results obtained gravimetrically expressed as mg of lipid per grams of liver; (b) shows results expressed as mg of lipid per whole liver. Mice were fed diets for 8 weeks. Values represent means ± SEM (). Significant difference between N and HF mice using one-way ANOVA: ***. Significant difference among HF and HFLG, HFHG, HFLC, and HFHC mice using one-way ANOVA: ^###.

(a)

(b)

3.6. Effect of Green Tea and Cocoa Tea Supplementations on Plasma Lipid in Mice Given High-Fat Diet

Plasma lipid levels of mice are shown in Table 6. Compared to N-fed mice, HF mice had significantly elevated levels of plasma TG and Chol. Both green tea and cocoa tea additions resulted in significant reduced levels of plasma TG and Chol at either dose. However, there was no significant difference on TG or Chol between 2% green tea and cocoa tea supplemented groups or between 4% green tea and cocoa tea supplemented groups.

3.7. Effect of Green Tea and Cocoa Tea Supplementations on Hepatic Gene Expression in Mice Given High-Fat Diet

In order to shed light on the mechanism by which cocoa tea extract contributes to its beneficial effects, mRNA levels of proteins controlling lipid metabolism in the liver were determined (Figure 5). Relative mRNA levels were compared by expressing levels relative to N mice. High-fat diet tended to increase level of expression of genes controlling cholesterol uptake—LDL-R, and cholesterol synthesis—HMG Co-A reductase, which were tended to be lowered by green tea and cocoa tea supplementations. mRNA levels for genes involved in fatty acid uptake, CD36 was also higher in HF group. Likewise, green tea and cocoa tea supplementations dose-dependently reduced the level of expression. mRNA levels for the transcription factor controlling lipid metabolism, PPAR-γ was markedly increased by high-fat diet. Both green tea and cocoa tea supplementations dose-dependently downregulated the expression at 2% and 4%, however only 2% and 4% green tea and 4% cocoa tea supplementation had reached statistical significance.

(a)

(b)

(c)

(d)

4. Discussion

The present study demonstrates that the addition of cocoa tea to mice on a high-fat diet (containing 21% butterfat and 0.15% cholesterol) resulted in a dose-dependent reduction in: (a) body weight, (b) fat pad mass (epididymal, perirenal and inguinal fat), (c) liver weight, (d) total liver lipid, (e) liver triglyceride and cholesterol, and (f) plasma lipid levels. These results provided evidence for the first time indicating that cocoa tea has a potential beneficial effect on weight control and lipid metabolism in C57BL/6 mice with diet-induced obesity. We are also the first time comparing the effects of cocoa tea and green tea using a diet-induced mice model which mimics human with metabolic syndrome.

Over the years, the beneficial effects of dietary green tea on plasma and hepatic lipid levels have been well documented in various animal studies [8, 9, 28, 29]. The positive findings from these pre-clinical studies have also been confirmed in a number of human clinical trials suggesting the antiobesity effect of green tea extract [7, 30, 31]. The beneficial effects of green tea have been attributed to the presence of tea catechins, in particularly EGCG [32–34]. Our data pertaining to the catechins contents of both tea extracts (Table 2) indicate that the major type of catechins in green tea extract was EGCG. This was however not the case for cocoa tea extract, which contained only approximately one-seventh the amount of EGCG detected in green tea extract, but with higher quantities of other catechins such as GCG and C. Previous work using GCG produced by heat epimerization of EGCG suggested GCG are more effective in lowering plasma cholesterol concentration compared to EGCG, possibly because GCG are more effective in inhibiting lymphatic absorption of endogenous cholesterol [35–37], but not triglyceride [36]. In consonance with these studies, when comparing the individual Chol and TG lowering effects of green tea and cocoa tea in our animal experiment, it appeared that green tea extract are more potent in lowering both plasma and hepatic TG, whereby cocoa tea extract are comparatively more potent in lowering plasma and hepatic Chol. The above studies therefore support the notion that GCG has played a role in contributing the beneficial effects of cocoa tea.

The preceding discussion assumes that the lipid-lowering and hepatoprotective properties of cocoa tea extract are dependent on its catechins content and/or its distinct catechin composition. It cannot be ruled out however, that the noncatechins containing portion of cocoa tea extract may also be responsible for the observed effects. HPLC analysis suggested that cocoa tea extract also contained high levels of theobromine. Although researches focusing on the effect of theobromine on lipid metabolism are limited, Eteng and Ettarh showed that acute theobromine administration (700 mg/kg) caused significant reduction in total serum cholesterol, and triglycerides [38]. Only additional studies with fractionated cocoa tea will provide the necessary evidence as to determine the bioactive component of cocoa tea extract.

A number of different mechanisms could be responsible for the beneficial effects of cocoa tea on obesity and plasma and liver lipid metabolism. It had been suggested that green tea catechins could exert modifications in appetite control, leading to decreased nutrient absorption and thereby contributing to a downregulation of enzymes involved in lipid metabolism within the liver and adipose tissues [39, 40]. In the present study, 4% green tea supplemented animals had significantly reduced appetite, as evidenced by the reduced food intake compared to high-fat-fed animals. This was however not the case for cocoa tea supplemented animals. Cocoa tea supplementation dose-dependently reduced the body weight and plasma and hepatic lipid without affecting the food intake of the animals. Furthermore, this reduction in hepatic cholesterol levels induced by cocoa tea extract was associated with a trend in the reduction in the expression of enzymes affecting cholesterol uptake (LDL-R) and cholesterol synthesis (HMG Co-A reductase). Cocoa tea could also downregulate the expression of enzyme affecting fatty acid uptake (CD36), thereby leading to its TG-lowering effect. Interestingly, cocoa tea could reduce high-fat diet-induced increase in PPAR-γ expression. PPAR-γ is a ligand-activated transcription factor that played an important role in the regulation of lipid and glucose metabolisms. It regulates a serial of genes involved in lipid metabolism including SCD-1, CD36, FAS, LDL-R, and SREBP-1. In rodent models of metabolic syndrome demonstrating diet-induced hepatic steatosis and obesity, hepatic expression of PPARγ is markedly upregulated [41, 42]. The fact that the elevated transcription levels of PPARγ and its targeted genes including LDL-R, HMG Co-A reductase and CD36 in the livers of high-fat-fed mice are dose dependently downregulated in cocoa tea supplemented animals suggested cocoa tea could possibly regulate hepatic lipid metabolism via PPAR-γ regulated pathway. Kurihara et al. suggested that cocoa tea reduced blood TG via suppression of lymphatic TG absorption [25]. Whether the effect of cocoa tea supplementation on body weight and downregulation of plasma and liver lipid observed in our study was due to the ability of cocoa tea to primarily regulate hepatic PPAR-γ expression and its targeted genes or secondary as a result of reduced lipid absorption within the intestine, the present study has the limitation in providing direct evidence of reduced lipid absorption and/or reduced bile acid production. Additional experiments including gene and protein expression analysis within the liver, adipose tissues, and intestine will be required to define which of these effects of cocoa tea are primary and secondary.

The potent ability of dietary cocoa tea to reduce both plasma and liver lipid content in high-fat-fed mice, to an extent similar to green tea of the same dosage, suggests it might be of therapeutic benefit in humans with diet-induced metabolic syndrome, in particularly for obese individuals with hyperlipidemia and nonalcoholic fatty liver disease (NAFLD). NAFLD affects 10–20% of the general population and is commonly found in obese or diabetic patients [43]. At present, there is no established treatment for it, and current suggested management strategy relies on diet regimen, weight loss, and exercise. Dietary supplements/nutraceuticals that might help to delay the development or alleviate this condition are therefore of great importance [44, 45]. Although green tea promotes beneficial effect on health, the fact that green tea contains caffeine has caused various concerns. Caffeine can cause insomnia, anxiety, irritability, upset stomach, nausea, diarrhea, or frequent urination [46] and has been reported to cause interact with various drugs [47]. It is generally recommended that green tea should not be taken by patients suffering from heart conditions or major cardiovascular problems [9, 48]. Pregnant and breastfeeding women and children are suggested not to drink more than one or two cups per day due to their slow detoxification rate of caffeine [8, 19]. Current green tea decaffeination technique predominately relies on the use of supercritical carbon dioxide fluid extraction (SC-CO₂) method. Although this method has great advantages over conventional methods which employ the use of solvents that could be toxic [19], SC-CO₂ are relatively cost ineffective and require high capital costs for batch extraction [49]. During the decaffeination process, much of the volatile and aroma-active compounds in the green tea will also be removed, thereby resulting in weaker aroma and stronger bitter taste [19, 50]. The fact that cocoa tea, being a naturally occurring tea plant, contains no caffeine therefore poses major advantage. This unique feature of cocoa tea also provides an opportunity for the more feasible through-the-day consumption, so that it could be integrated with the daily dietary regimen of obese individuals and subjects with cardiovascular problems, without the excitatory effects of caffeine. Further studies will help to determine whether cocoa tea is of therapeutic benefit in patients with NAFLD or in overweight and insulin-resistant individuals at increased risk of coronary artery disease.

In conclusion, the present study indicates that cocoa tea has a beneficial effect on obesity, hepatomegaly, hepatic steatosis, and elevated plasma lipid levels in mice fed with a high-fat diet. These results provide the proof of concept that cocoa tea, which contains no caffeine, might be of therapeutic value as a nutraceutical in patients with increased risk of fatty liver disease and/or cardiovascular disease. Furthermore, the unique feature of the naturally decaffeinated cocoa tea has posed major advantage over green tea or decaffeinated green tea in providing individuals whom are prohibited from caffeine intake with the feasibility and flexibility to enjoy the benefits of tea, without the concern of the side effects induced by caffeine or the high cost incurred during the processing of decaffeinated green tea.

Acknowledgment

The authors would like to thank Mr. Li Kai Kai for his technical support with HPLC analysis of all tea extracts.

References

C. Pitsavos, D. Panagiotakos, M. Weinem, and C. Stefanadis, “Diet, exercise and the metabolic syndrome,” The Review of Diabetic Studies, vol. 3, no. 3, pp. 118–126, 2006.
View at: Google Scholar
P. L. Huang, “A comprehensive definition for metabolic syndrome,” DMM Disease Models and Mechanisms, vol. 2, no. 5-6, pp. 231–237, 2009.
View at: Publisher Site | Google Scholar
E. S. Ford, “Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the U.S,” Diabetes Care, vol. 28, no. 11, pp. 2745–2749, 2005.
View at: Publisher Site | Google Scholar
H.-M. Lakka, D. E. Laaksonen, T. A. Lakka et al., “The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men,” Journal of the American Medical Association, vol. 288, no. 21, pp. 2709–2716, 2002.
View at: Publisher Site | Google Scholar
S. M. Grundy, “Metabolic syndrome: therapeutic considerations,” Handbook of Experimental Pharmacology, no. 170, pp. 107–133, 2005.
View at: Google Scholar
S. M. Grundy, “Metabolic syndrome: a multiplex cardiovascular risk factor,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 2, pp. 399–404, 2007.
View at: Publisher Site | Google Scholar
K. A. Grove and J. D. Lambert, “Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesity,” Journal of Nutrition, vol. 140, no. 3, pp. 446–453, 2010.
View at: Publisher Site | Google Scholar
S. M. Chacko, P. T. Thambi, R. Kuttan, and I. Nishigaki, “Beneficial effects of green tea: a literature review,” Chinese Medicine, vol. 5, article 13, 2010.
View at: Publisher Site | Google Scholar
C. Cabrera, R. Artacho, and R. Giménez, “Beneficial effects of green tea—a review,” Journal of the American College of Nutrition, vol. 25, no. 2, pp. 79–99, 2006.
View at: Google Scholar
S. Sae-Tan, K. A. Grove, and J. D. Lambert, “Weight control and prevention of metabolic syndrome by green tea,” Pharmacological Research, vol. 64, no. 2, pp. 146–154, 2011.
View at: Publisher Site | Google Scholar
D. A. Balentine, S. A. Wiseman, and L. C. M. Bouwens, “The chemistry of tea flavonoids,” Critical Reviews in Food Science and Nutrition, vol. 37, no. 8, pp. 693–704, 1997.
View at: Google Scholar
J. D. Lambert, J. Hong, G.-Y. Yang, J. Liao, and C. S. Yang, “Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations,” The American Journal of Clinical Nutrition, vol. 81, supplement 1, pp. 284S–291S, 2005.
View at: Google Scholar
C. S. Yang, P. Maliakal, and X. Meng, “Inhibition of carcinogenesis by tea,” Annual Review of Pharmacology and Toxicology, vol. 42, pp. 25–54, 2002.
View at: Publisher Site | Google Scholar
C. S. Yang and J. M. Landau, “Effects of tea consumption nutrition health,” Journal of Nutrition, vol. 130, no. 10, pp. 2409–2412, 2000.
View at: Google Scholar
A. G. Dulloo, J. Seydoux, L. Girardier, P. Chantre, and J. Vandermander, “Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity,” International Journal of Obesity, vol. 24, no. 2, pp. 252–258, 2000.
View at: Google Scholar
A. Belza, S. Toubro, and A. Astrup, “The effect of caffeine, green tea and tyrosine on thermogenesis and energy intake,” European Journal of Clinical Nutrition, vol. 63, no. 1, pp. 57–64, 2009.
View at: Publisher Site | Google Scholar
A. Smith, “Effects of caffeine on human behavior,” Food and Chemical Toxicology, vol. 40, no. 9, pp. 1243–1255, 2002.
View at: Publisher Site | Google Scholar
I. Hindmarch, U. Rigney, N. Stanley, P. Quinlan, J. Rycroft, and J. Lane, “A naturalistic investigation of the effects of day-long consumption of tea, coffee and water on alertness, sleep onset and sleep quality,” Psychopharmacology, vol. 149, no. 3, pp. 203–216, 2000.
View at: Publisher Site | Google Scholar
S. M. Lee, H.-S. Lee, K.-H. Kim, and K.-O. Kim, “Sensory characteristics and consumer acceptability of decaffeinated green teas,” Journal of Food Science, vol. 74, no. 3, pp. S135–S141, 2009.
View at: Publisher Site | Google Scholar
X. Wang, D. Wang, J. Li, C. Ye, and K. Kubota, “Aroma characteristics of Cocoa tea (Camellia ptilophylla Chang),” Bioscience, Biotechnology and Biochemistry, vol. 74, no. 5, pp. 946–953, 2010.
View at: Publisher Site | Google Scholar
H. T. Chang, C. X. Ye, R. M. Chang, Y. D. Ma, and P. Zhang, “A discovery of a new tea resource-cocoa tea tree containing theobromine from China,” Acta Scientiarum Naturalium Universitatis Sunyatseni, no. 3, pp. 131–133, 1988.
View at: Google Scholar
X. Bingfen, L. Zongchao, P. Qichao et al., “The anticancer effect and anti-DNA topoisomerase II effect of extracts of camellia ptilophylla chang and camellia sinesis,” Chinese Journal of Cancer Research, vol. 6, no. 3, pp. 184–190, 1994.
View at: Publisher Site | Google Scholar
L. Peng, N. Khan, F. Afaq, C. Ye, and H. Mukhtar, “In vitro and in vivo effects of water extract of white cocoa tea (Camellia ptilophylla) against human prostate cancer,” Pharmaceutical Research, vol. 27, no. 6, pp. 1128–1137, 2010.
View at: Publisher Site | Google Scholar
X.-R. Yang, Y.-Y. Wang, K.-K. La et al., “Inhibitory effects of cocoa tea (Camellia ptilophylla) in human hepatocellular carcinoma HepG2 in vitro and in vivo through apoptosis,” Journal of Nutritional Biochemistry, 2011.
View at: Publisher Site | Google Scholar
H. Kurihara, H. Shibata, Y. Fukui et al., “Evaluation of the hypolipemic property of Camellia sinensis var. ptilophylla on postprandial hypertriglyceridemia,” Journal of Agricultural and Food Chemistry, vol. 54, no. 14, pp. 4977–4981, 2006.
View at: Publisher Site | Google Scholar
E. G. Bligh and W. J. Dyer, “A rapid method of total lipid extraction and purification,” Canadian Journal of Biochemistry and Physiology, vol. 37, no. 8, pp. 911–917, 1959.
View at: Google Scholar
H. Harris, “On the rapid conversion of haematoxylin into haematein in staining reactions,” Journal of Applied Microbiology, vol. 3, pp. 777–780, 1900.
View at: Google Scholar
G. Zheng, K. Sayama, T. Okubo, L. R. Juneja, and I. Oguni, “Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice,” In Vivo, vol. 18, no. 1, pp. 55–62, 2004.
View at: Google Scholar
T. Murase, A. Nagasawa, J. Suzuki, T. Hase, and I. Tokimitsu, “Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver,” International Journal of Obesity, vol. 26, no. 11, pp. 1459–1464, 2002.
View at: Publisher Site | Google Scholar
A. Basu, K. Sanchez, M. J. Leyva et al., “Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome,” Journal of the American College of Nutrition, vol. 29, no. 1, pp. 31–40, 2010.
View at: Google Scholar
L. Hooper, P. A. Kroon, E. B. Rimm et al., “Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials,” American Journal of Clinical Nutrition, vol. 88, no. 1, pp. 38–50, 2008.
View at: Google Scholar
N. T. Zaveri, “Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications,” Life Sciences, vol. 78, no. 18, pp. 2073–2080, 2006.
View at: Publisher Site | Google Scholar
M. Bose, J. D. Lambert, J. Ju, K. R. Reuhl, S. A. Shapses, and C. S. Yang, “The major green tea polyphenol, (−)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice,” Journal of Nutrition, vol. 138, no. 9, pp. 1677–1683, 2008.
View at: Google Scholar
S. Wolfram, “Effects of green tea and EGCG on cardiovascular and metabolic health,” Journal of the American College of Nutrition, vol. 26, no. 4, 2007.
View at: Google Scholar
I. Ikeda, M. Kobayashi, T. Hamada et al., “Heat-epimerized tea catechins rich in gallocatechin gallate and catechin gallate are more effective to inhibit cholesterol absorption than tea catechins rich in epigallocatechin gallate and epicatechin gallate,” Journal of Agricultural and Food Chemistry, vol. 51, no. 25, pp. 7303–7307, 2003.
View at: Publisher Site | Google Scholar
S. M. Lee, C. W. Kim, J. K. Kim, H. J. Shin, and J. H. Baik, “GCG-rich tea catechins are effective in lowering cholesterol and triglyceride concentrations in hyperlipidemic rats,” Lipids, vol. 43, no. 5, pp. 419–429, 2008.
View at: Publisher Site | Google Scholar
M. Kobayashi, T. Unno, Y. Suzuki et al., “Heat-epimerized tea catechins have the same cholesterol-lowering activity as green tea catechins in cholesterol-fed rats,” Bioscience, Biotechnology and Biochemistry, vol. 69, no. 12, pp. 2455–2458, 2005.
View at: Publisher Site | Google Scholar
M. U. Eteng and R. R. Ettarh, “Comparative effects of theobromine and cocoa extract on lipid profile in rats,” Nutrition Research, vol. 20, no. 10, pp. 1513–1517, 2000.
View at: Google Scholar
J.-K. Lin and S.-Y. Lin-Shiau, “Mechanisms of hypolipidemic and anti-obesity effects of tea and tea polyphenols,” Molecular Nutrition and Food Research, vol. 50, no. 2, pp. 211–217, 2006.
View at: Publisher Site | Google Scholar
S. Wolfram, Y. Wang, and F. Thielecke, “Anti-obesity effects of green tea: from bedside to bench,” Molecular Nutrition and Food Research, vol. 50, no. 2, pp. 176–187, 2006.
View at: Publisher Site | Google Scholar
A. Vidal-Puig, M. Jimenez-Liñan, B. B. Lowell et al., “Regulation of PPAR γ gene expression by nutrition and obesity in rodents,” Journal of Clinical Investigation, vol. 97, no. 11, pp. 2553–2561, 1996.
View at: Google Scholar
R. K. Semple, V. K. K. Chatterjee, and S. O'Rahilly, “PPARγ and human metabolic disease,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 581–589, 2006.
View at: Publisher Site | Google Scholar
G. C. Farrell and C. Z. Larter, “Nonalcoholic fatty liver disease: from steatosis to cirrhosis,” Hepatology, vol. 43, no. 2, pp. S99–S112, 2006.
View at: Publisher Site | Google Scholar
P. Portincasa, I. Grattagliano, V. O. Palmieri, and G. Palasciano, “Current pharmacological treatment of nonalcoholic fatty liver,” Current Medicinal Chemistry, vol. 13, no. 24, pp. 2889–2900, 2006.
View at: Publisher Site | Google Scholar
M. Cave, I. Deaciuc, C. Mendez et al., “Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition,” Journal of Nutritional Biochemistry, vol. 18, no. 3, pp. 184–195, 2007.
View at: Publisher Site | Google Scholar
M. A. Heckman, J. Weil, and E. G. de Mejia, “Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters,” Journal of Food Science, vol. 75, no. 3, pp. R77–R87, 2010.
View at: Publisher Site | Google Scholar
J. A. Carrillo and J. Benitez, “Clinically significant pharmacokinetic interactions between dietary caffeine and medications,” Clinical Pharmacokinetics, vol. 39, no. 2, pp. 127–153, 2000.
View at: Google Scholar
M. C. Cornelis and A. El-Sohemy, “Coffee, caffeine, and coronary heart disease,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 10, no. 6, pp. 745–751, 2007.
View at: Publisher Site | Google Scholar
J. P. Friedrich and E. H. Pryde, “Supercritical CO₂ extraction of lipid-bearing materials and characterization of the products,” Journal of the American Oil Chemists' Society, vol. 61, no. 2, pp. 223–228, 1984.
View at: Publisher Site | Google Scholar
S. Lee, M. K. Park, K. H. Kim, and Y.-S. Kim, “Effect of supercritical carbon dioxide decaffeination on volatile components of green teas,” Journal of Food Science, vol. 72, no. 7, pp. S497–S502, 2007.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2013 Xiao Rong Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

3025

Downloads

1961

Citations